PeptideFactSheetsAn independent reference
Menu

Choline-containing supplement compound · Fact sheet

Alpha-GPC

Also known as Choline alfoscerate · L-alpha-glycerylphosphorylcholine

Alpha-GPC is a choline-containing compound with a controlled Alzheimer-dementia study and smaller performance research. An observational association with later stroke raises a safety question but does not prove causation.

Not FDA approvedEarly human evidence
Brain, mood & sleepMuscle & recovery

What is Alpha-GPC?

It supplies choline through a glycerophosphocholine structure. It is not the same compound as citicoline.

A dementia medicine study cannot establish improved performance in healthy athletes.

Benefits & claims

Interest in Alpha-GPC spans cognition and sleep, recovery. Study findings apply to the named formulation and population.

What the evidence supports

  • The dementia study favored choline alfoscerate on selected cognitive and clinical scales.
  • The observational stroke study cannot determine whether the compound caused the higher observed risk.
  • Neither source establishes that healthy people obtain durable cognitive or strength benefits.
Research areas
  • Formulation-specific human outcomes
  • Mechanistic research

Dosage & frequency

Human study context

This is an exposure from a named human study, not a generally established treatment or enhancement regimen.

Choline alfoscerate randomized dementia trial

261 adults with mild to moderate Alzheimer-type dementia

Amount
400 mg capsule
Frequency
Three times daily for 180 days
Route studied or labeled
Oral

Historical disease-specific trial. It does not establish an athletic or healthy-person regimen, and does not resolve the later observational stroke question.

Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • A dementia medicine study cannot establish improved performance in healthy athletes.

Interactions & precautions

  • The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.

What is still unresolved

  • Reproducibility in larger independent trials
  • Long-term outcomes and adverse effects
  • Equivalence of different preparations and interaction profiles
Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Alpha-GPC and subsequent stroke: cohort study FDA: what approval means for supplements

Side effects & risks

  • The long-term stroke association warrants further study; it is not an absolute risk estimate for every supplement user.
  • Underlying illness, prescription patterns and other factors may explain part of an observational association.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

A 261-person six-month dementia trial reported cognitive-scale improvements. A large Korean claims-based cohort associated prescription exposure with later stroke, with residual confounding possible.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 2 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

Clearer reading and more energy, alongside headaches

An author with ADHD described clearer reading, more energy and a brighter mood after alpha-GPC, but also headaches after each of two exposures and another headache the next morning.

Reported use in this account

Product
Alpha-GPC capsule
Amount
150 mg
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Two consecutive days described

Other exposures described: Vyvanse; Existing multi-supplement routine; Eggs and a nap

Vyvanse, eggs, a nap and an established multi-supplement routine were concurrent. The brief account cannot isolate alpha-GPC or establish a treatment effect for ADHD.

Read the original account
Mixed account · personal report

Brief focus changes followed by low mood and demotivation

A separate author described more vivid colors and some extra focus on the first day, followed by low mood and demotivation the next day. They also reported irregular heartbeats that stopped after discontinuation, while acknowledging uncertainty about the connection.

Reported use in this account

Product
Alpha-GPC capsule
Amount
150 mg, as identified in the title
Frequency
One capsule on the first day of the described exposure
Route
Not specified clearly
Duration
A three-day symptom sequence, reportedly repeated four or five times

The author said the pattern occurred several times, but no clinical rhythm diagnosis or product verification was supplied. Speculative biochemical explanations in replies are not evidence of the cause.

Read the original account

Approval status

No FDA-approved Alpha-GPC drug indication is established for the supplement uses discussed here. Supplement availability is not FDA approval of efficacy or safety.

No FDA-approved product for this entry

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Reproducibility in larger independent trials
  • Long-term outcomes and adverse effects
  • Equivalence of different preparations and interaction profiles

Summary

Neither source establishes that healthy people obtain durable cognitive or strength benefits.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  2. journalAlpha-GPC and subsequent stroke: cohort study

    Observational prescription-data analysis; association does not establish causation.

  3. fdaFDA: what approval means for supplements

    Dietary supplements are not approved by FDA for safety and effectiveness before marketing.

How we assess sources · Suggest a correction